# Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

> **NCT04635735** · PHASE1,PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT04635735
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-12
- **Primary completion:** 2023-02-02
- **Final completion:** 2023-02-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04635735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04635735, "Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04635735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*